Cargando…

Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study

BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is a devastating autoimmune disorder with cycles of escalating relapse. Rates of diagnosis in the elderly are increasing. Therapeutic decision-making is more challenging in elderly patients due to multiple comorbidities and high risk of drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Weihe, Jiao, Yujuan, Cui, Lei, Zhang, Yeqiong, Jiao, Jinsong, Jin, Ming, Yuan, Wei, You, Yang, Wang, Renbin, Peng, Dantao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041617/
https://www.ncbi.nlm.nih.gov/pubmed/36993936
http://dx.doi.org/10.1177/17562864231162420
_version_ 1784912760095637504
author Zhang, Weihe
Jiao, Yujuan
Cui, Lei
Zhang, Yeqiong
Jiao, Jinsong
Jin, Ming
Yuan, Wei
You, Yang
Wang, Renbin
Peng, Dantao
author_facet Zhang, Weihe
Jiao, Yujuan
Cui, Lei
Zhang, Yeqiong
Jiao, Jinsong
Jin, Ming
Yuan, Wei
You, Yang
Wang, Renbin
Peng, Dantao
author_sort Zhang, Weihe
collection PubMed
description BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is a devastating autoimmune disorder with cycles of escalating relapse. Rates of diagnosis in the elderly are increasing. Therapeutic decision-making is more challenging in elderly patients due to multiple comorbidities and high risk of drug-induced side effects. OBJECTIVE: This retrospective study assessed the efficacy and safety of standard plasma exchange (PLEX) treatment in an elderly population with NMOSD. DESIGN: Seventy-six patients with NMOSD who received PLEX were apportioned to two groups as either elderly (⩾60 years, n = 26) or young (<60 years) at the time of the first procedure. METHODS: Therapeutic response was judged according to functional recovery at 6 months, as reflected by Expanded Disability Status Scale (EDSS) and visual outcome scale (VOS) scores. RESULTS: The mean age of the 26 elderly patients was 67.7 ± 7.9 years (range 60–87 years); the population was predominantly female (88.5%). PLEX sessions were generally well tolerated among the elderly. Compared with the young patients, the elderly had significantly more comorbidities and concomitant medications. Twenty-four (96.0%) elderly patients showed functional improvement at 6 months after PLEX, of which 15 (60.0%) experienced moderate-to-marked improvement. Six months after the initial PLEX treatment, the patients overall experienced a significant improvement in EDSS and VOS scores. Logistic regression showed that severe optic neuritis attack was a significant independent prognostic factor associated with poor PLEX response. The groups were comparable regarding overall or serious adverse events. The rate of transient hypotension was significantly higher in the elderly compared with the young. CONCLUSION: PLEX is an effective and safe therapy for elderly patients with NMOSD and should be considered a treatment option during NMOSD attacks. In the elderly, preventive measures against hypotension are recommended before PLEX.
format Online
Article
Text
id pubmed-10041617
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-100416172023-03-28 Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study Zhang, Weihe Jiao, Yujuan Cui, Lei Zhang, Yeqiong Jiao, Jinsong Jin, Ming Yuan, Wei You, Yang Wang, Renbin Peng, Dantao Ther Adv Neurol Disord Original Research BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is a devastating autoimmune disorder with cycles of escalating relapse. Rates of diagnosis in the elderly are increasing. Therapeutic decision-making is more challenging in elderly patients due to multiple comorbidities and high risk of drug-induced side effects. OBJECTIVE: This retrospective study assessed the efficacy and safety of standard plasma exchange (PLEX) treatment in an elderly population with NMOSD. DESIGN: Seventy-six patients with NMOSD who received PLEX were apportioned to two groups as either elderly (⩾60 years, n = 26) or young (<60 years) at the time of the first procedure. METHODS: Therapeutic response was judged according to functional recovery at 6 months, as reflected by Expanded Disability Status Scale (EDSS) and visual outcome scale (VOS) scores. RESULTS: The mean age of the 26 elderly patients was 67.7 ± 7.9 years (range 60–87 years); the population was predominantly female (88.5%). PLEX sessions were generally well tolerated among the elderly. Compared with the young patients, the elderly had significantly more comorbidities and concomitant medications. Twenty-four (96.0%) elderly patients showed functional improvement at 6 months after PLEX, of which 15 (60.0%) experienced moderate-to-marked improvement. Six months after the initial PLEX treatment, the patients overall experienced a significant improvement in EDSS and VOS scores. Logistic regression showed that severe optic neuritis attack was a significant independent prognostic factor associated with poor PLEX response. The groups were comparable regarding overall or serious adverse events. The rate of transient hypotension was significantly higher in the elderly compared with the young. CONCLUSION: PLEX is an effective and safe therapy for elderly patients with NMOSD and should be considered a treatment option during NMOSD attacks. In the elderly, preventive measures against hypotension are recommended before PLEX. SAGE Publications 2023-03-23 /pmc/articles/PMC10041617/ /pubmed/36993936 http://dx.doi.org/10.1177/17562864231162420 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Zhang, Weihe
Jiao, Yujuan
Cui, Lei
Zhang, Yeqiong
Jiao, Jinsong
Jin, Ming
Yuan, Wei
You, Yang
Wang, Renbin
Peng, Dantao
Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study
title Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study
title_full Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study
title_fullStr Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study
title_full_unstemmed Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study
title_short Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study
title_sort therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041617/
https://www.ncbi.nlm.nih.gov/pubmed/36993936
http://dx.doi.org/10.1177/17562864231162420
work_keys_str_mv AT zhangweihe therapeuticefficacyandsafetyofplasmapheresisinelderlypatientswithneuromyelitisopticaspectrumdisorderasinglecenterobservationalstudy
AT jiaoyujuan therapeuticefficacyandsafetyofplasmapheresisinelderlypatientswithneuromyelitisopticaspectrumdisorderasinglecenterobservationalstudy
AT cuilei therapeuticefficacyandsafetyofplasmapheresisinelderlypatientswithneuromyelitisopticaspectrumdisorderasinglecenterobservationalstudy
AT zhangyeqiong therapeuticefficacyandsafetyofplasmapheresisinelderlypatientswithneuromyelitisopticaspectrumdisorderasinglecenterobservationalstudy
AT jiaojinsong therapeuticefficacyandsafetyofplasmapheresisinelderlypatientswithneuromyelitisopticaspectrumdisorderasinglecenterobservationalstudy
AT jinming therapeuticefficacyandsafetyofplasmapheresisinelderlypatientswithneuromyelitisopticaspectrumdisorderasinglecenterobservationalstudy
AT yuanwei therapeuticefficacyandsafetyofplasmapheresisinelderlypatientswithneuromyelitisopticaspectrumdisorderasinglecenterobservationalstudy
AT youyang therapeuticefficacyandsafetyofplasmapheresisinelderlypatientswithneuromyelitisopticaspectrumdisorderasinglecenterobservationalstudy
AT wangrenbin therapeuticefficacyandsafetyofplasmapheresisinelderlypatientswithneuromyelitisopticaspectrumdisorderasinglecenterobservationalstudy
AT pengdantao therapeuticefficacyandsafetyofplasmapheresisinelderlypatientswithneuromyelitisopticaspectrumdisorderasinglecenterobservationalstudy